Binosto®

The First and Only Buffered Solution for the Treatment of Osteoporosis

Pharmaceutical Form:

Binosto® (buffered alendronate sodium 70mg) is an effervescent tablet for oral solution.

Binosto® (buffered alendronate sodium 70mg) is an easy-to-swallow, buffered oral solution that represents a true breakthrough in the treatment of osteoporosis – especially for those patients who prefer not to swallow tablets, or have difficulties swallowing pills. Taken just once a week, with a reduced volume of water to drink and no risk of a tablet getting lodged in the esophagus, Binosto® has the potential to improve long-term patient compliance and adherence to therapy, thereby decreasing the risk of disabling fractures.

Indication:

Europe: Treatment of osteoporosis in postmenopausal women. Binosto® 70 mg reduces the risk of vertebral and hip fractures.

United States: Treatment of osteoporosis in postmenopausal women. Binosto® increases bone mass and reduces the incidence of fractures, including those of the hip and spine. Binosto® is indicated for treatment to increase bone mass in men with osteoporosis.

Binosto® Global Footprint

Binosto® has recently been approved in Europe, Russia, South Korea, Taiwan and Australia and is commercialized under the name Steovess® in France. EffRx is currently looking for Partners to commercialize Binosto® in selected European countries, Latin America and the Asia-Pacific.

Please visit www.binosto.co.uk for the EU approved prescribing information.

For Business Development inquiries please contact: info@effrx.com.

Binosto® is available by prescription in the United States to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.

Visit www.binosto.com for U.S. approved prescribing information.

Disclaimer:
Information for Healthcare professionals only. Please refer to the official prescribing information and approved indications, contraindications, and warnings in your country.